ICON Executive and Leadership Team

Linda Baddour, the Chief Financial Officer at ICON, directs all global fiscal operations and capital allocation strategies. Managing the financial health of the organization, the Chief Financial Officer ensures rigorous compliance with international reporting standards while supporting the expansion of clinical research services. This leadership role involves overseeing investor relations and optimizing the balance sheet to fund long-term growth initiatives across North American and European markets. By implementing robust financial controls, Linda Baddour directly impacts the ability of the company to scale its drug development infrastructure. Baddour maintains alignment with the Board regarding quarterly performance targets and long-term value creation. Through precise fiscal management, the Chief Financial Officer secures the necessary resources for the continued advancement of medical device commercialization projects, ensuring the firm remains a leader in the competitive global life sciences sector.

Connie Inguanti, the President, Symphony Health at ICON, directs the strategic application of data analytics to support commercialization services for the pharmaceutical industry. Overseeing the integration of real-world evidence, the President, Symphony Health ensures that clients gain actionable insights into patient outcomes and market dynamics. This leadership role involves managing large-scale data platforms that track drug performance across global healthcare systems. By leveraging advanced analytics, Connie Inguanti directly impacts the ability of biotechnology firms to optimize their market access strategies. Inguanti coordinates with internal research teams to translate complex data sets into clear, evidence-based recommendations for medical device manufacturers. Through the continuous refinement of analytical tools, the President, Symphony Health drives operational efficiency and enhances the value proposition of the company, ultimately supporting the broader mission of improving public health through data-driven decision-making.

Thomas Marsland, the President at ICON, directs the overarching operational execution of clinical development and commercialization services. Overseeing the alignment of cross-functional teams, the President ensures that the company meets the complex requirements of global pharmaceutical and government partners. This leadership role involves driving organizational efficiency and fostering innovation in service delivery models across international regions. By streamlining internal processes, Thomas Marsland directly impacts the speed and quality of drug development projects. Marsland works closely with other C-suite leaders to implement growth strategies that expand the market presence of the firm. Through the management of large-scale operational initiatives, the President supports the delivery of high-value solutions that address the evolving needs of the biotechnology sector, ensuring that the company maintains a competitive edge in the global research and development landscape.

Deepali Suri, the President, ICON Biotech at ICON, directs the specialized development services tailored for the unique needs of the biotechnology sector. Overseeing the end-to-end lifecycle of drug development, the President, ICON Biotech ensures that emerging biotech firms receive the necessary support to navigate complex regulatory and clinical landscapes. This leadership role involves architecting customized research programs that accelerate the transition from early-stage discovery to commercialization. By focusing on the specific challenges faced by smaller, innovation-driven companies, Deepali Suri directly impacts the success rate of new medical therapies. Suri coordinates with global teams to provide scalable resources that facilitate rapid project execution. Through the strategic management of the biotech division, the President, ICON Biotech drives significant growth for the company, ensuring that the firm remains a primary partner for organizations seeking to bring transformative medical solutions to the global market.

Suzanne Gagnon, the Chief Medical Officer at ICON, directs clinical safety protocols and medical strategy for complex drug development programs. Overseeing global medical affairs, the Chief Medical Officer ensures that all research activities adhere to the highest ethical and regulatory standards across diverse therapeutic areas. This leadership role involves collaborating with pharmaceutical partners to design efficient clinical trials that accelerate the path to market for new medical devices. By providing expert medical guidance, Suzanne Gagnon directly impacts the quality and reliability of data generated for public health organizations. Gagnon monitors emerging health trends to refine the clinical development methodology used by the firm. Through the integration of advanced medical insights, the Chief Medical Officer drives the success of international research initiatives, ensuring that the company consistently delivers high-impact solutions for biotechnology clients worldwide.